title: [Results of trabeculectomy with anti-VGEF therapy in the treatment of neovascular glaucoma secondary to retinal vein occlusion (report of 21 cases followed at Bukavu Eye Clinic from January 1 to December 31th, 2015)].
abstract: OBJECTIVE
  To evaluate the results of anti-VGEF with trabeculectomy in the treatment of neovascular glaucoma, a severe complication of retinal vein occlusion (RVO).
  
  
  METHODS
  This is a prospective case series of consecutive patients with neovascular glaucoma secondary to retinal vein occlusion. All patients underwent panretinal photocoagulation and a mean of 3 anti-VEGF injections prior to trabeculectomy. Ophthalmic parameters were recorded pre- and postoperatively: visual acuity (VA), intraocular pressure (IOP), iris examination, gonioscopy and fundus examination, and as necessary, fluorescein angiography. Minimum follow-up was 9 months.
  
  
  RESULTS
  Twenty-one eyes of 21 patients were included. The mean preoperative intraocular pressure was 38mmHg (31-45mmHg). Postoperatively, the mean IOP was 15mmHg (13-19mmHg). IOP reduction was observed in all eyes after surgery and stayed finally stabilized in nineteen eyes (90.5 %). The rubeosis had definitively disappeared an average of two weeks after injection, but VA decreased in all patients. Nineteen patients (90.5 %) maintained preservation of their eyes. Two eyes underwent evisceration.
  
  
  CONCLUSIONS
  In most cases, trabeculectomy with anti-VGEF halted anterior segment neovascularization. It allowed for surgery on a quiet, normotensive eye, with good postoperative results. While functional rehabilitation was not achieved, the globe was able to be preserved in 90.5 % of cases.
authors.affiliation: Clinique ophtalmologique de Bukavu, RD Congo, BP : 144, Cyangugu, Rwanda; Université de Lubumbashi RD Congo, Lubumbashi, RD, Congo. Electronic address: thkabesha@yahoo.com.
authors.forename: T B
authors.initials: TB
authors.lastname: Kabesha
authors.affiliation: Clinique ophtalmologique de Bukavu, RD Congo, BP : 144, Cyangugu, Rwanda.
authors.forename: D
authors.initials: D
authors.lastname: Kabesha
authors.affiliation: Université de Lubumbashi RD Congo, Lubumbashi, RD, Congo.
authors.forename: V
authors.initials: V
authors.lastname: Maloba
authors.affiliation: Université de Lubumbashi RD Congo, Lubumbashi, RD, Congo.
authors.forename: C
authors.initials: C
authors.lastname: Mwamba
authors.affiliation: Université de Lubumbashi RD Congo, Lubumbashi, RD, Congo.
authors.forename: B
authors.initials: B
authors.lastname: Chenge
authors.affiliation: Université de Lubumbashi RD Congo, Lubumbashi, RD, Congo.
authors.forename: A
authors.initials: A
authors.lastname: Mukalay
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery*; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000379:methods; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy* / Q000601:surgery*; D012432:Rwanda; D014130:Trabeculectomy; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Anti-VEGF; GNV; Intraocular pressure; Neovascular glaucoma; Pression intraoculaire; Results; Résultats; Trabeculectomy; Trabéculectomie